文献速递心律失常

早发房颤患者心肌病与心律失常基因罕见变异与死亡率的关系

Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes.
PubMed 文献 · JAMA Cardiol · 2022-01-01

本研究基于TOPMed项目前瞻性队列,纳入1293例66岁前诊断房颤且接受全基因组测序的患者,评估145个心肌病与心律失常基因中罕见变异与死亡时间的关联。中位随访9.9年,219例(17%)死亡;

要点

  • 早发房颤患者中10%携带心肌病/心律失常基因疾病相关变异。
  • 携带者死亡风险升高(HR 1.5,95%CI 1.0-2.1),诊断年龄越轻风险越高。
  • 基因检测或可为早发房颤提供预后信息。

核心结论

  • 心肌病与心律失常基因罕见变异可能与早发房颤患者死亡风险增加相关,尤其年轻诊断者。
  • 基因检测可能为早发房颤患者提供重要预后信息。

研究设计与样本

  • 通过NHLBI TOPMed项目进行全基因组测序,分析145个商业临床基因检测面板中的心肌病与心律失常基因罕见变异。
  • 主要结局为死亡时间,由医疗记录和国家死亡指数判定,采用多变量Cox比例风险回归分析。

主要发现

  • 中位随访9.9年(IQR 6.9-13.2),219例(17%)死亡。
  • 131例(10%)携带疾病相关(致病或可能致病)罕见变异。

关键数值与推荐

  • 疾病相关变异定义为致病或可能致病罕见变异。
  • 最常见基因的携带者死亡率:TTN 26%(10/38)、MYH7 33%(6/18)、LMNA 22%(2/9)、MYH6 0%(0/10)、KCNQ1 0%(0/8)。
  • 死亡原因包括心肌病相关死亡73例、猝死40例、卒中相关死亡10例。

临床怎么用

  • 对早发房颤患者可考虑基因检测以识别心肌病与心律失常基因疾病相关变异,辅助预后评估。
  • 携带疾病相关变异且年轻诊断房颤者死亡风险更高,可能需要更密切随访。
  • 关注BMI和LVEF等可干预因素,较高BMI和较低LVEF与死亡风险增加相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with early-onset atrial fibrillation (AF) are enriched for rare variants in cardiomyopathy and arrhythmia genes. The clinical significance of these rare variants in patients with early-onset AF is unknown. OBJECTIVE: To assess the association between rare variants in cardiomyopathy and arrhythmia genes detected in patients with early-onset AF and time to death. DESIGN, SETTING, AND PARTICIPANTS: This prospective cohort study included participants with AF diagnosed before 66 years of age who underwent whole-genome sequencing through the National Heart, Lung and Blood Institute's Trans-Omics for Precision Medicine program. Participants were enrolled from November 23, 1999, to June 2, 2015. Data were analyzed from February 26 to September 19, 2021. EXPOSURES: Rare variants identified in a panel of 145 genes that are included in cardiomyopathy and arrhythmia panels used by commercial clinical genetic testing laboratories. MAIN OUTCOMES AND MEASURES: The primary study outcome was time to death and was adjudicated from medical records and the National Death Index. Multivariable Cox proportional hazards regression was used to evaluate the association of disease-associated variants with risk of death after adjustment for age at AF diagnosis, sex, race, body mass index, left ventricular ejection fraction, and an interaction term of age at AF diagnosis and disease-associated variant status. RESULTS: Among 1293 participants (934 [72%] male; median age at enrollment, 56.0 years; IQR, 48.0-61.0 years), disease-associated (pathogenic or likely pathogenic) rare variants were found in 131 (10%). During a median follow-up of 9.9 years (IQR, 6.9-13.2 years), 219 participants (17%) died. In univariable analysis, disease-associated variants were associated with an increased risk of mortality (hazard ratio, [HR], 1.5; 95% CI, 1.0-2.1; P = .05); the association remained significant in multivariable modeling when adjusted for age at AF diagnosis, sex, race, body mass index, left ventricular ejection fraction, and an interaction term between disease-associated variant status and age at AF diagnosis. The interaction demonstrated that disease-associated variants were associated with a significantly higher risk of mortality compared with no disease-associated variant when AF was diagnosed at a younger age (P = .008 for interaction). Higher body mass index (per IQR: HR, 1.4; 95% CI, 1.2-1.6; P < .001) and lower left ventricular ejection fraction (per IQR: HR, 0.8; 95% CI, 0.7-0.8; P < .001) were associated with higher mortality risk. There were 73 cardiomyopathy-related deaths, 40 sudden deaths, and 10 stroke-related deaths. Mortality among patients with the most prevalent genes with disease-associated variants was 26% (10 of 38 patients) for TTN, 33% (6 of 18) for MYH7, 22% (2 of 9) for LMNA, 0% (0 of 10) for MYH6, and 0% (0 of 8) for KCNQ1. CONCLUSIONS AND RELEVANCE: The findings suggest that rare variants in cardiomyopathy and arrhythmia genes may be associated with increased risk of mortality among patients with early-onset AF, especially those diagnosed at a younger age. Genetic testing may provide important prognostic information for patients with early-onset AF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Yoneda, Anderson, Ye, et al. Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol. 2022. PMID: 35544069. doi:10.1001/jamacardio.2022.0810

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。